
RNAi Therapeutics Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030
Description
RNAi Therapeutics Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030
The report on the global RNAi therapeutics market provides qualitative and quantitative analysis for the period from 2021-2030. The global RNAi therapeutics market was valued at USD 11.20 billion in 2022 and is expected to reach USD 20.23 billion in 2030, with a CAGR of a 7.69% during the forecast period 2023-2030. The study on RNAi therapeutics market covers the analysis of the leading geographies such as North America, Europe, Asia Pacific, and RoW for the period of 2021-2030.
The report on RNAi therapeutics market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global RNAi therapeutics market over the period of 2021-2030. Moreover, the report is a collective presentation of primary and secondary research findings.
Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global RNAi therapeutics market over the period of 2021-2030. Further, IGR- Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.
Report Findings
1) Drivers
- The substantial growth in the RNAi therapeutics market is strongly influenced by heightened research and development efforts aimed at addressing chronic diseases.
- The increasing collaboration activities between drug distribution companies and contract research organizations (CROs) contribute to the growth of the RNAi therapeutics market.
- Complex delivery mechanisms hinder RNAi therapeutics market.
- Technological breakthroughs in delivery technology have increased the number of indications for RNAi therapeutics, provides an opportunity for the market to grow.
A) Primary Research
Our primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include
1. Key Opinion Leaders associated with Infinium Global Research
2. Internal and External subject matter experts
3. Professionals and participants from the industry
Our primary research respondents typically include
1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.
B) Secondary Research
Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. At Infinium Global Research, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.
The secondary sources of the data typically include
1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies
Segment Covered
The global RNAi therapeutics market is segmented on the basis of type, application, route of administration, and end user.
The Global RNAi Therapeutics Market by Type
- Small interfering RNA (siRNA)
- MicroRNA (miRNA)
- Genetic Disorders
- Oncology
- Neurodegenerative Disorders
- Infectious Diseases
- Renal Diseases
- Others
- Intradermal Injections
- Pulmonary Delivery
- Intravenous Injections
- Diagnostic Laboratories
- Research and Academic Laboratories
- Hospitals
The companies covered in the report include
- Alnylam Pharmaceuticals, Inc.
- QIAGEN
- Olix Pharmaceuticals, Inc.
- Arbutus Biopharma
- Silence Therapeutics
- Dicerna Pharmaceuticals, Inc
- Arrowhead Pharmaceuticals, Inc.
- Quark Software Inc.
- Phio Pharmaceuticals
- Benitec Biopharma Ltd
1. Comprehensive analysis of the global as well as regional markets of the RNAi therapeutics market.
2. Complete coverage of all the segments in the RNAi therapeutics market to analyze the trends, developments in the global market and forecast of market size up to 2030.
3. Comprehensive analysis of the companies operating in the global RNAi therapeutics market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. IGR- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.
Table of Contents
300 Pages
- Chapter 1. Preface
- 1.1. Report Description
- 1.2. Research Methods
- 1.3. Research Approaches
- Chapter 2. Executive Summary
- 2.1. RNAi Therapeutics Market Highlights
- 2.2. RNAi Therapeutics Market Projection
- 2.3. RNAi Therapeutics Market Regional Highlights
- Chapter 3. Global RNAi Therapeutics Market Overview
- 3.1. Introduction
- 3.2. Market Dynamics
- 3.2.1. Drivers
- 3.2.2. Restraints
- 3.2.3. Opportunities
- 3.3. Porter's Five Forces Analysis
- 3.4. IGR-Growth Matrix Analysis
- 3.4.1. IGR-Growth Matrix Analysis by Type
- 3.4.2. IGR-Growth Matrix Analysis by Application
- 3.4.3. IGR-Growth Matrix Analysis by Route Of Administration
- 3.4.4. IGR-Growth Matrix Analysis by End User
- 3.4.5. IGR-Growth Matrix Analysis by Region
- 3.5. Value Chain Analysis of RNAi Therapeutics Market
- Chapter 4. RNAi Therapeutics Market Macro Indicator Analysis
- Chapter 5. Company Profiles and Competitive Landscape
- 5.1. Competitive Landscape in the Global RNAi Therapeutics Market
- 5.2. Companies Profiles
- 5.2.1. Alnylam Pharmaceuticals, Inc.
- 5.2.2. QIAGEN
- 5.2.3. Olix Pharmaceuticals, Inc.
- 5.2.4. Arbutus Biopharma
- 5.2.5. Silence Therapeutics
- 5.2.6. Dicerna Pharmaceuticals, Inc
- 5.2.7. Arrowhead Pharmaceuticals, Inc.
- 5.2.8. Quark Software Inc.
- 5.2.9. Phio Pharmaceuticals
- 5.2.10. Benitec Biopharma Ltd
- Chapter 6. Global RNAi Therapeutics Market by Type
- 6.1. Small interfering RNA (siRNA)
- 6.2. MicroRNA (miRNA)
- Chapter 7. Global RNAi Therapeutics Market by Application
- 7.1. Genetic Disorders
- 7.2. Oncology
- 7.3. Neurodegenerative Disorders
- 7.4. Infectious Diseases
- 7.5. Renal Diseases
- 7.6. Others
- Chapter 8. Global RNAi Therapeutics Market by Route Of Administration
- 8.1. Intradermal Injections
- 8.2. Pulmonary Delivery
- 8.3. Intravenous Injections
- Chapter 9. Global RNAi Therapeutics Market by End User
- 9.1. Diagnostic Laboratories
- 9.2. Research and Academic Laboratories
- 9.3. Hospitals
- Chapter 10. Global RNAi Therapeutics Market by Region 2023-2030
- 10.1. North America
- 10.1.1. North America RNAi Therapeutics Market by Type
- 10.1.2. North America RNAi Therapeutics Market by Application
- 10.1.3. North America RNAi Therapeutics Market by Route Of Administration
- 10.1.4. North America RNAi Therapeutics Market by End User
- 10.1.5. North America RNAi Therapeutics Market by Country
- 10.1.5.1. The U.S. RNAi Therapeutics Market
- 10.1.5.1.1. The U.S. RNAi Therapeutics Market by Type
- 10.1.5.1.2. The U.S. RNAi Therapeutics Market by Application
- 10.1.5.1.3. The U.S. RNAi Therapeutics Market by Route Of Administration
- 10.1.5.1.4. The U.S. RNAi Therapeutics Market by End User
- 10.1.5.2. Canada RNAi Therapeutics Market
- 10.1.5.2.1. Canada RNAi Therapeutics Market by Type
- 10.1.5.2.2. Canada RNAi Therapeutics Market by Application
- 10.1.5.2.3. Canada RNAi Therapeutics Market by Route Of Administration
- 10.1.5.2.4. Canada RNAi Therapeutics Market by End User
- 10.1.5.3. Mexico RNAi Therapeutics Market
- 10.1.5.3.1. Mexico RNAi Therapeutics Market by Type
- 10.1.5.3.2. Mexico RNAi Therapeutics Market by Application
- 10.1.5.3.3. Mexico RNAi Therapeutics Market by Route Of Administration
- 10.1.5.3.4. Mexico RNAi Therapeutics Market by End User
- 10.2. Europe
- 10.2.1. Europe RNAi Therapeutics Market by Type
- 10.2.2. Europe RNAi Therapeutics Market by Application
- 10.2.3. Europe RNAi Therapeutics Market by Route Of Administration
- 10.2.4. Europe RNAi Therapeutics Market by End User
- 10.2.5. Europe RNAi Therapeutics Market by Country
- 10.2.5.1. Germany RNAi Therapeutics Market
- 10.2.5.1.1. Germany RNAi Therapeutics Market by Type
- 10.2.5.1.2. Germany RNAi Therapeutics Market by Application
- 10.2.5.1.3. Germany RNAi Therapeutics Market by Route Of Administration
- 10.2.5.1.4. Germany RNAi Therapeutics Market by End User
- 10.2.5.2. United Kingdom RNAi Therapeutics Market
- 10.2.5.2.1. United Kingdom RNAi Therapeutics Market by Type
- 10.2.5.2.2. United Kingdom RNAi Therapeutics Market by Application
- 10.2.5.2.3. United Kingdom RNAi Therapeutics Market by Route Of Administration
- 10.2.5.2.4. United Kingdom RNAi Therapeutics Market by End User
- 10.2.5.3. France RNAi Therapeutics Market
- 10.2.5.3.1. France RNAi Therapeutics Market by Type
- 10.2.5.3.2. France RNAi Therapeutics Market by Application
- 10.2.5.3.3. France RNAi Therapeutics Market by Route Of Administration
- 10.2.5.3.4. France RNAi Therapeutics Market by End User
- 10.2.5.4. Italy RNAi Therapeutics Market
- 10.2.5.4.1. Italy RNAi Therapeutics Market by Type
- 10.2.5.4.2. Italy RNAi Therapeutics Market by Application
- 10.2.5.4.3. Italy RNAi Therapeutics Market by Route Of Administration
- 10.2.5.4.4. Italy RNAi Therapeutics Market by End User
- 10.2.5.5. Rest of Europe RNAi Therapeutics Market
- 10.2.5.5.1. Rest of Europe RNAi Therapeutics Market by Type
- 10.2.5.5.2. Rest of Europe RNAi Therapeutics Market by Application
- 10.2.5.5.3. Rest of Europe RNAi Therapeutics Market by Route Of Administration
- 10.2.5.5.4. Rest of Europe RNAi Therapeutics Market by End User
- 10.3. Asia Pacific
- 10.3.1. Asia Pacific RNAi Therapeutics Market by Type
- 10.3.2. Asia Pacific RNAi Therapeutics Market by Application
- 10.3.3. Asia Pacific RNAi Therapeutics Market by Route Of Administration
- 10.3.4. Asia Pacific RNAi Therapeutics Market by End User
- 10.3.5. Asia Pacific RNAi Therapeutics Market by Country
- 10.3.5.1. China RNAi Therapeutics Market
- 10.3.5.1.1. China RNAi Therapeutics Market by Type
- 10.3.5.1.2. China RNAi Therapeutics Market by Application
- 10.3.5.1.3. China RNAi Therapeutics Market by Route Of Administration
- 10.3.5.1.4. China RNAi Therapeutics Market by End User
- 10.3.5.2. Japan RNAi Therapeutics Market
- 10.3.5.2.1. Japan RNAi Therapeutics Market by Type
- 10.3.5.2.2. Japan RNAi Therapeutics Market by Application
- 10.3.5.2.3. Japan RNAi Therapeutics Market by Route Of Administration
- 10.3.5.2.4. Japan RNAi Therapeutics Market by End User
- 10.3.5.3. India RNAi Therapeutics Market
- 10.3.5.3.1. India RNAi Therapeutics Market by Type
- 10.3.5.3.2. India RNAi Therapeutics Market by Application
- 10.3.5.3.3. India RNAi Therapeutics Market by Route Of Administration
- 10.3.5.3.4. India RNAi Therapeutics Market by End User
- 10.3.5.4. South Korea RNAi Therapeutics Market
- 10.3.5.4.1. South Korea RNAi Therapeutics Market by Type
- 10.3.5.4.2. South Korea RNAi Therapeutics Market by Application
- 10.3.5.4.3. South Korea RNAi Therapeutics Market by Route Of Administration
- 10.3.5.4.4. South Korea RNAi Therapeutics Market by End User
- 10.3.5.5. Australia RNAi Therapeutics Market
- 10.3.5.5.1. Australia RNAi Therapeutics Market by Type
- 10.3.5.5.2. Australia RNAi Therapeutics Market by Application
- 10.3.5.5.3. Australia RNAi Therapeutics Market by Route Of Administration
- 10.3.5.5.4. Australia RNAi Therapeutics Market by End User
- 10.3.5.6. Rest of Asia-Pacific RNAi Therapeutics Market
- 10.3.5.6.1. Rest of Asia-Pacific RNAi Therapeutics Market by Type
- 10.3.5.6.2. Rest of Asia-Pacific RNAi Therapeutics Market by Application
- 10.3.5.6.3. Rest of Asia-Pacific RNAi Therapeutics Market by Route Of Administration
- 10.3.5.6.4. Rest of Asia-Pacific RNAi Therapeutics Market by End User
- 10.4. RoW
- 10.4.1. RoW RNAi Therapeutics Market by Type
- 10.4.2. RoW RNAi Therapeutics Market by Application
- 10.4.3. RoW RNAi Therapeutics Market by Route Of Administration
- 10.4.4. RoW RNAi Therapeutics Market by End User
- 10.4.5. RoW RNAi Therapeutics Market by Sub-region
- 10.4.5.1. Latin America RNAi Therapeutics Market
- 10.4.5.1.1. Latin America RNAi Therapeutics Market by Type
- 10.4.5.1.2. Latin America RNAi Therapeutics Market by Application
- 10.4.5.1.3. Latin America RNAi Therapeutics Market by Route Of Administration
- 10.4.5.1.4. Latin America RNAi Therapeutics Market by End User
- 10.4.5.2. Middle East RNAi Therapeutics Market
- 10.4.5.2.1. Middle East RNAi Therapeutics Market by Type
- 10.4.5.2.2. Middle East RNAi Therapeutics Market by Application
- 10.4.5.2.3. Middle East RNAi Therapeutics Market by Route Of Administration
- 10.4.5.2.4. Middle East RNAi Therapeutics Market by End User
- 10.4.5.3. Africa RNAi Therapeutics Market
- 10.4.5.3.1. Africa RNAi Therapeutics Market by Type
- 10.4.5.3.2. Africa RNAi Therapeutics Market by Application
- 10.4.5.3.3. Africa RNAi Therapeutics Market by Route Of Administration
- 10.4.5.3.4. Africa RNAi Therapeutics Market by End User
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.